Breakthrough Collaboration Ignites Hope for Duchenne Muscular Dystrophy with Novel Gene Therapy

BOSTON, MA & TOKYO, JAPAN – September 14, 2026 – A significant milestone in the pursuit of effective treatments for Duchenne muscular dystrophy (DMD) has been reached as Exegenesis Bio and Modalis Therapeutics formally activate their research partnership and licence agreement. This collaboration is poised to accelerate the development of MDL-201, a groundbreaking therapeutic candidate that combines Modalis’s innovative CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology with Exegenesis Bio’s advanced engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. The agreement, which officially becomes effective today, grants Modalis the rights to leverage EMC181 in the advancement of MDL-201, signaling a potent alliance against a devastating genetic disorder.

n

DMD, a severe and progressive muscle-wasting disease, currently lacks a definitive cure, leaving a critical unmet medical need. The MDL-201 programme aims to address this by selectively and sustainably activating utrophin expression in muscle tissue. This approach is particularly promising as it seeks to provide a therapeutic solution independent of the specific genetic mutation in the dystrophin gene, which is responsible for DMD. By circumventing the complexities of mutation-specific treatments, MDL-201 holds the potential to offer a broad-spectrum therapy that could benefit a significantly larger patient population.

n

The synergy between Exegenesis Bio’s precision AAV delivery system and Modalis’s novel gene modulation technique is at the heart of this partnership. EMC181 is specifically engineered for enhanced and targeted delivery to muscle tissue, a crucial factor in treating a systemic muscular disorder. Concurrently, its design aims to reduce exposure to off-target organs, such as the liver, which could substantially improve the safety profile of MDL-201. This strategic combination is expected to pave the way for a more effective, safer, and broadly applicable therapeutic option for individuals living with DMD.

n

A Deeper Dive into the Collaboration: Main Facts and Strategic Imperatives

n

The newly activated partnership between Exegenesis Bio and Modalis Therapeutics represents a convergence of cutting-edge genetic engineering and targeted delivery mechanisms. At its core, the agreement is designed to leverage the distinct strengths of both companies to tackle the formidable challenge of Duchenne muscular dystrophy.

n

The Core of the Agreement:nUnder the terms of the licence agreement, Modalis Therapeutics is granted crucial rights to integrate Exegenesis Bio’s EMC181 AAV capsid into the development pathway of MDL-201. This is not merely a transfer of technology but a deeply integrated collaborative effort where the specialized delivery capabilities of EMC181 will be married with the therapeutic payload of Modalis’s CRISPR-GNDM system. The formal effective date of September 14, 2026, marks the official commencement of this strategic alliance, allowing both parties to fully engage in the joint development efforts.

n

MDL-201: A Mutation-Independent Approach:nThe primary objective of MDL-201 is to address DMD by activating utrophin expression in muscle cells. Utrophin is a protein functionally similar to dystrophin, the protein that is deficient or absent in DMD patients due to genetic mutations. By upregulating utrophin, MDL-201 aims to compensate for the missing dystrophin, thereby restoring muscle function and integrity. The key innovation here lies in the CRISPR-GNDM technology’s ability to achieve this activation independent of the specific underlying dystrophin gene mutation. This distinguishes MDL-201 from many current gene therapies that are often limited to specific subsets of patients based on their genetic profiles.

n

EMC181: Precision Delivery and Enhanced Safety:nExegenesis Bio’s EMC181 capsid is a critical component of this strategy. AAV vectors are widely recognized as effective delivery vehicles for gene therapies due to their low immunogenicity and ability to infect various cell types. However, challenges remain in achieving highly specific tissue targeting and minimizing off-target effects. EMC181 has been specifically engineered to overcome these limitations, demonstrating enhanced tropism for muscle tissue while simultaneously reducing uptake by non-target organs like the liver. This "liver-detargeting" property is paramount for improving the safety profile of systemically administered gene therapies, as liver toxicity and immune responses are significant concerns.

n

The combination of these technologies is not just an incremental improvement but a potentially transformative leap. Efficiently targeting muscle tissues while reducing systemic exposure is crucial for maximizing therapeutic efficacy and minimizing adverse events, a dual benefit that could significantly enhance the overall patient experience and long-term viability of the treatment.

n

A Chronology of Innovation and Strategic Positioning

n

The current partnership is built upon a foundation of ongoing research and strategic advancements by both Exegenesis Bio and Modalis Therapeutics. While the formal activation date for this specific agreement is today, the journey towards MDL-201 has been paved with earlier successes and a clear vision for the future of genetic medicine.

n

Key Dates and Milestones:

n

n
• September 2024: Modalis Therapeutics achieved a significant regulatory milestone by being awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for its congenital muscular dystrophy type 1a (LAMA2-CMD) gene therapy. This designation underscores Modalis’s expertise in rare neurological disorders and validates its innovative CRISPR-based gene therapy platforms. This earlier success highlights the company’s growing pipeline and its commitment to addressing severe paediatric conditions.

n

• Today, September 14, 2026: The research partnership and licence agreement between Exegenesis Bio and Modalis Therapeutics officially becomes effective, marking the formal initiation of the MDL-201 development program under this collaborative framework. While the groundwork for this agreement would have been laid well in advance, its official commencement signals the operational start of integrated efforts.

n

n

This chronological overview places the current agreement within a broader context of Modalis’s strategic advancements in the rare disease space. The FDA designation for LAMA2-CMD demonstrates regulatory recognition of their technology and approach, lending credibility and momentum to their subsequent ventures, including the MDL-201 program. For Exegenesis Bio, this partnership exemplifies their strategy of applying their next-generation AAV capsid platform to high-impact gene therapies, selecting partners with promising payloads to address critical unmet medical needs.

n

Supporting Data: Unpacking the Science and Disease Landscape

n

To fully appreciate the significance of MDL-201, it is essential to delve into the complexities of Duchenne muscular dystrophy, the mechanisms of the technologies involved, and the rationale behind their synergistic application.

n

The Devastating Impact of Duchenne Muscular Dystrophy (DMD)

n

DMD is the most common and severe form of muscular dystrophy, affecting approximately 1 in 3,500 to 5,000 male births worldwide. It is an X-linked recessive disorder caused by mutations in the DMD gene, which encodes for dystrophin, a crucial protein located on the sarcolemma (muscle cell membrane). Dystrophin plays a vital role in maintaining the structural integrity of muscle fibres during contraction.

n

Without functional dystrophin, muscle cells become highly susceptible to damage, leading to a relentless cycle of degeneration and regeneration. Over time, the regenerative capacity of the muscle is exhausted, and muscle tissue is progressively replaced by fibrotic tissue and fat, resulting in irreversible weakness.

n

n
• Clinical Presentation: Symptoms typically appear in early childhood, often between ages 2 and 3, with delayed motor milestones. Affected boys gradually lose the ability to walk, usually requiring a wheelchair by their early teens.

n

• Progression: The disease progresses to affect respiratory muscles, leading to respiratory failure, and cardiac muscle, causing cardiomyopathy, which are the leading causes of mortality. The average life expectancy for individuals with DMD has improved in recent decades due to better supportive care, but it still often extends only into the 20s or early 30s.

n

• Challenges in Treatment: The large size of the DMD gene (2.2 million base pairs, with 79 exons), the wide variety of mutations (deletions, duplications, point mutations), and the systemic nature of muscle degeneration pose significant challenges for therapeutic development.

n

Current Treatment Landscape and Unmet Needs

Existing treatments for DMD primarily focus on symptom management and slowing disease progression.

• Corticosteroids: Prednisone and deflazacort are the cornerstone of care, helping to preserve muscle strength and function, reduce inflammation, and delay the loss of ambulation. However, they come with significant side effects, including weight gain, bone fragility, and behavioural changes.
• Exon-Skipping Therapies: These RNA-based therapies (e.g., eteplirsen, golodirsen, viltolarsen, casimersen) aim to restore the reading frame of the DMD gene during mRNA processing, leading to the production of a truncated but partially functional dystrophin protein. While a significant advancement, these therapies are mutation-specific, only applicable to patients with amenable mutations (e.g., exon 51, 53, or 45 skipping), thereby excluding a large percentage of the DMD population.
• Micro-dystrophin Gene Therapy: Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec) is a recently approved AAV-based gene therapy that delivers a micro-dystrophin gene. This therapy aims to provide a functional mini-dystrophin protein to muscle cells. While representing a major breakthrough, this approach also faces challenges related to immune response to the AAV vector, potential limitations in long-term expression, and the size constraints of the AAV capsid which necessitate a truncated version of dystrophin.

Despite these advancements, there remains a critical unmet need for therapies that are:

1. Mutation-independent: Applicable to all DMD patients, regardless of their specific genetic mutation.
2. Highly efficacious: Capable of substantially restoring muscle function and integrity.
3. Safe: With minimal off-target effects and manageable immunogenicity.
4. Long-lasting: Providing sustained therapeutic benefit.

MDL-201, with its novel approach, directly targets these unmet needs.

The Science Behind MDL-201: A Dual-Technology Approach

The collaborative effort between Exegenesis Bio and Modalis Therapeutics hinges on the complementary nature of their proprietary technologies.

Modalis’s CRISPR-GNDM: Utrophin Activation for Broad Efficacy

Modalis Therapeutics’ core technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation), is a sophisticated gene modulation platform derived from the revolutionary CRISPR-Cas system. Unlike traditional CRISPR-Cas9 systems that induce double-strand breaks to edit genes (insertions, deletions, corrections), CRISPR-GNDM employs a "dead" Cas protein (dCas9) or similar effector that is catalytically inactive. This dCas9 is guided by a guide RNA (gRNA) to specific DNA sequences, but instead of cutting the DNA, it acts as a precise tether for effector proteins.

In the context of MDL-201, the CRISPR-GNDM system is engineered to recruit transcriptional activators to the promoter region of the utrophin gene. Utrophin is a paralog of dystrophin, meaning it’s a gene related by duplication to dystrophin. During foetal development, utrophin is expressed in muscle cells, but its expression is significantly downregulated after birth. However, studies have shown that sustained upregulation of utrophin in DMD muscles can functionally compensate for the absence of dystrophin, improving muscle pathology and function.

The advantages of CRISPR-GNDM for utrophin activation are significant:

• Non-mutagenic: Because it modulates gene expression rather than cutting DNA, it avoids the risks associated with permanent genomic alterations, such as off-target editing or chromosomal translocations.
• Mutation-independent: Utrophin activation is effective regardless of the specific mutation in the dystrophin gene. This broad applicability is a game-changer for DMD, potentially offering a single therapeutic strategy for the entire patient population.
• Sustained Expression: Delivered via an AAV vector, the CRISPR-GNDM machinery can lead to long-term utrophin expression from a single administration, addressing the need for durable therapeutic effects in a chronic disease.

Exegenesis Bio’s EMC181: Precision Delivery and Enhanced Safety

Adeno-associated viruses (AAVs) are among the most promising viral vectors for gene therapy due to their excellent safety profile, ability to transduce various cell types, and sustained gene expression. However, systemic administration of AAVs, particularly at high doses needed for muscle diseases, presents several challenges:

• Off-target Transduction: Wild-type AAV serotypes (e.g., AAV9, AAVrh74) can transduce multiple organs, including the liver, heart, and brain. While some off-target transduction may be acceptable, excessive liver uptake can lead to dose-limiting hepatotoxicity and robust immune responses against the AAV capsid, potentially hindering re-dosing.
• Immunogenicity: The human population has varying levels of pre-existing antibodies to common AAV serotypes, which can neutralize the therapeutic vector and prevent successful gene transfer.
• Dose Requirements: Muscle diseases like DMD require widespread transduction of a large tissue mass, often necessitating high systemic doses, which exacerbates off-target effects and immunogenicity concerns.

Exegenesis Bio’s EMC181 capsid is a proprietary, engineered AAV variant designed to overcome these limitations. Through advanced capsid engineering techniques (e.g., directed evolution, rational design), EMC181 has been optimized for:

• Enhanced Muscle Tropism: Significantly improved ability to target and transduce muscle cells compared to conventional AAV serotypes. This means a larger proportion of the viral dose reaches the intended therapeutic target.
• Liver Detargeting: Reduced uptake and transduction of liver cells. This critical feature is expected to decrease the risk of hepatotoxicity and lower the overall systemic viral load required to achieve therapeutic levels in muscle, thereby improving the safety profile.
• Reduced Immunogenicity (potential): While not explicitly stated, engineered capsids often aim to reduce susceptibility to pre-existing antibodies or to elicit a milder immune response, allowing for potentially higher effective doses or even re-dosing strategies in the future.

The Synergy of CRISPR-GNDM and EMC181

The combination of these two advanced technologies creates a powerful therapeutic platform for MDL-201:

• Efficient and Targeted Delivery: EMC181 ensures that the CRISPR-GNDM machinery is delivered precisely and effectively to the vast and distributed muscle tissue throughout the body, maximizing the therapeutic payload’s reach.
• Maximized Therapeutic Benefit, Minimized Risk: By concentrating the therapeutic effect in muscle and minimizing exposure to the liver, the combination aims for an optimal balance of efficacy and safety, which is crucial for long-term treatment of a chronic disease like DMD.
• Broad Patient Applicability: The mutation-independent nature of utrophin activation, coupled with efficient and safe delivery, offers the potential for a single therapeutic product to address the needs of nearly all DMD patients, simplifying development, regulatory pathways, and clinical implementation.

Strategic Rationale and Official Perspectives

The executives from both companies have articulated a clear vision for this partnership, emphasizing its strategic importance and the potential impact on patient care.

Leadership Voices on the Partnership

Zhenhua Wu, CEO of Exegenesis Bio, expressed enthusiasm for the collaboration: “We are pleased to collaborate with Modalis to advance MDL-201. EMC181 was developed to enable efficient muscle targeting while reducing liver exposure, and we believe its combination with Modalis’ innovative CRISPR-GNDM payload represents a compelling approach for DMD.”

Wu’s statement underscores Exegenesis Bio’s core competency in AAV capsid engineering and its commitment to applying this technology to areas of high unmet medical need. The explicit mention of "efficient muscle targeting" and "reducing liver exposure" highlights the critical safety and efficacy advantages that EMC181 is designed to provide. His confidence in the "compelling approach for DMD" signifies a belief in the synergistic potential of the combined technologies.

He further added, “This collaboration reflects our strategy of applying our next-generation AAV capsid platform to differentiated gene therapies with the potential to address significant unmet medical needs.” This emphasizes Exegenesis Bio’s business model: to partner its advanced delivery platforms with promising therapeutic payloads from other innovative companies, thereby maximizing the impact of its foundational technology across a broader range of genetic diseases.

While Modalis Therapeutics did not provide a direct quote on the scientific aspects of the partnership in the provided information, their statement regarding the financial implications offers insight into their corporate perspective. Modalis indicated that the financial effects of this partnership are expected to be immaterial for the current fiscal year, and no changes to the full-year earnings forecast have been made. This suggests that while strategically important, the initial financial commitments or upfront payments associated with this agreement are not expected to significantly impact their short-term financial outlook, allowing them to maintain stable projections. This also implies a focus on long-term value creation through the successful development of MDL-201.

Addressing Market Needs and Future Vision

The collaboration is a direct response to the urgent need for more effective and accessible treatments for DMD. The current market, while seeing innovation, is still fragmented by mutation-specific therapies and burdened by safety concerns related to systemic gene therapy delivery.

The strategic vision behind MDL-201 is to create a "best-in-class" or even "first-in-class" therapy that offers universal applicability to DMD patients. By focusing on utrophin activation, the companies are moving beyond the limitations of correcting or replacing a mutated dystrophin gene, which is a complex and often mutation-specific endeavour. This broader applicability could significantly simplify the treatment paradigm for clinicians and broaden access for patients.

For Modalis, partnering with Exegenesis Bio provides access to a superior delivery vehicle that can unlock the full potential of their CRISPR-GNDM technology for a systemic disease like DMD. For Exegenesis Bio, this partnership validates their AAV capsid platform and secures its application in a high-profile rare disease program, further establishing their position as a leader in gene therapy delivery.

Broader Implications for Patients and the Industry

The Exegenesis Bio-Modalis Therapeutics collaboration carries far-reaching implications, not only for the Duchenne muscular dystrophy community but also for the broader field of genetic medicine and the biopharmaceutical industry.

A New Hope for DMD Patients

For the thousands of individuals and families affected by DMD, MDL-201 represents a beacon of renewed hope. The prospect of a mutation-independent therapy is particularly significant. It means that children diagnosed with DMD, regardless of their specific genetic mutation, could potentially benefit from the same treatment. This could:

• Expand Treatment Eligibility: Offer a therapeutic option to patients currently ineligible for mutation-specific exon-skipping therapies or micro-dystrophin gene therapies due to their genetic profile.
• Simplify Diagnosis and Treatment Decisions: Reduce the complexity of genetic screening for treatment eligibility, potentially streamlining the diagnostic-to-treatment pathway.
• Improve Safety Profile: The liver-detargeting properties of EMC181 are critical. Reduced off-target effects and improved safety can lead to better tolerability, allowing patients to stay on therapy longer and at optimal doses, maximizing therapeutic benefit and improving quality of life.
• Long-term Disease Management: If successful, a single administration of MDL-201 via AAV could lead to sustained utrophin expression, potentially slowing disease progression significantly and extending ambulation, respiratory function, and overall lifespan, while reducing the burden of daily treatments.

Advancing Gene Therapy Delivery and Specificity

This partnership underscores the ongoing evolution of gene therapy. The development of engineered AAV capsids like EMC181 is crucial for overcoming the limitations of first-generation AAV vectors. This collaboration serves as a proof-of-concept for:

• Targeted Delivery: Demonstrating that AAV vectors can be precisely engineered to achieve high tissue specificity, which is essential for systemic diseases where off-target effects can be detrimental.
• Improved Safety: Highlighting the importance of minimizing off-target organ exposure (e.g., liver detargeting) to enhance the safety profile of gene therapies, especially for chronic conditions requiring long-term expression.
• CRISPR Modulation Potential: Validating the therapeutic utility of CRISPR-GNDM as a non-mutagenic gene modulation tool, expanding the scope of CRISPR beyond gene editing to include sophisticated gene expression control. This could open doors for treating a wider array of genetic disorders without the inherent risks of permanent DNA alteration.

Economic and Market Impact

The Duchenne muscular dystrophy market is substantial, with current therapies commanding high prices due to the severity of the disease and the complexity of development. A successful, broadly applicable, and safer gene therapy like MDL-201 could significantly impact this market:

• Market Share: Position MDL-201 as a leading therapeutic option, potentially capturing a significant share of the DMD market.
• Investment and Innovation: Attract further investment into gene therapy research and development, particularly in AAV capsid engineering and CRISPR-based gene modulation, encouraging more innovation in the rare disease space.
• Strategic Partnerships: Serve as a model for future collaborations between companies specializing in delivery platforms and those with novel therapeutic payloads, fostering a more collaborative ecosystem for drug development.

Challenges and Future Outlook

While the promise of MDL-201 is immense, the path to clinical success is fraught with challenges inherent in developing novel genetic medicines.

Navigating the Path to Clinical Success

The journey from preclinical development to an approved therapy is long and complex. Key hurdles for MDL-201 will include:

• Preclinical Validation: Demonstrating robust and durable utrophin activation, functional improvement, and a strong safety profile in relevant animal models.
• Clinical Trials: Successfully navigating Phase 1, 2, and 3 clinical trials, which will require careful patient selection, rigorous safety monitoring, and clear efficacy endpoints. Immunogenicity to both the AAV capsid and the CRISPR-GNDM components will need to be thoroughly assessed.
• Manufacturing: Scaling up manufacturing of both the AAV vector and the CRISPR-GNDM components to meet clinical and eventual commercial demand, ensuring consistency and quality.
• Regulatory Approval: Obtaining regulatory approvals from agencies like the FDA and EMA will require compelling clinical data, a robust safety profile, and comprehensive manufacturing information.

The Horizon of Genetic Medicine

Despite these challenges, the Exegenesis Bio and Modalis Therapeutics partnership exemplifies the rapid advancements and growing sophistication within genetic medicine. The combination of highly specific gene modulation with precision delivery platforms represents the next wave of innovation. Such collaborations are vital for translating groundbreaking scientific discoveries into tangible therapies that can truly transform the lives of patients suffering from debilitating genetic diseases.

Conclusion

The formal activation of the research partnership and licence agreement between Exegenesis Bio and Modalis Therapeutics for MDL-201 marks a pivotal moment in the fight against Duchenne muscular dystrophy. By uniting Exegenesis Bio’s engineered muscle-tropic AAV capsid, EMC181, with Modalis’s innovative CRISPR-GNDM technology, the collaboration aims to deliver a mutation-independent, safe, and highly effective therapeutic solution for DMD. This strategic alliance not only offers a new ray of hope for patients and their families but also stands as a testament to the power of inter-company synergy in advancing the frontiers of genetic medicine, setting a new standard for targeted delivery and non-mutagenic gene modulation in the treatment of severe genetic disorders. The world watches with anticipation as MDL-201 progresses, holding the promise of a brighter future for those impacted by this relentless disease.